Literature DB >> 19726998

Frequency of long-term nonprogressors in HIV-1 seroconverters From Rakai Uganda.

Oliver Laeyendecker1, Andrew D Redd, Tom Lutalo, Ronald H Gray, Maria Wawer, Victor Ssempijja, Jordyn Gamiel, John Baptist Bwanika, Fred Makumbi, Fred Nalugoda, Pius Opendi, Godfrey Kigozi, Anthony Ndyanabo, Boaz Iga, Noah Kiwanuka, Nelson Sewankambo, Steven J Reynolds, David Serwadda, Thomas C Quinn.   

Abstract

OBJECTIVE: Studies on long-term nonprogressors (LTNP) have been conducted in the USA and Europe. This study examined the frequency of LTNPs and HIV controllers among 637 HIV-1 seroconverters in rural Uganda. DESIGN AND METHODS: LTNPs were defined as being infected for more than 7 years with a CD4 T-cell count above 600 cells per microliter, and HIV controllers as having undetectable viral loads on 3 separate occasions without antiretroviral treatment. HIV-1 viral load and subtype distribution between LTNP and non-LTNP populations were determined.
RESULTS: Of the HIV seroconverters, 9.1% (58/637) were LTNPs and 1.4% (9/637) were HIV controllers. LTNPs had a significantly lower viral load at set point than non-LTNP participants (P < 0.001). The Kaplan-Meier joint probability of surviving to 7 years with a CD4 count >600 was 19.2%. Individuals who survived 7 years had a significantly higher frequency of HIV-1 subtype A (P < 0.05), but seroconverters infected with HIV-1A did not have a significantly higher probability of becoming an LTNP.
CONCLUSIONS: The frequency of LTNPs appears to be relatively high in Uganda and it may be important to take this into account when designing studies of viral pathogenesis and performing HIV vaccine trials in sub-Saharan Africa.

Entities:  

Mesh:

Year:  2009        PMID: 19726998      PMCID: PMC2837462          DOI: 10.1097/QAI.0b013e3181bc08f5

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  23 in total

1.  Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression.

Authors:  J Tang; C Rivers; E Karita; C Costello; S Allen; P N Fultz; E E Schoenbaum; R A Kaslow
Journal:  Genes Immun       Date:  1999-09       Impact factor: 2.676

2.  Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1995.

Authors:  B A Koblin; B H van Benthem; S P Buchbinder; L Ren; E Vittinghoff; C E Stevens; R A Coutinho; G J van Griensven
Journal:  Am J Epidemiol       Date:  1999-11-15       Impact factor: 4.897

3.  CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.

Authors:  Matthew J Dolan; Hemant Kulkarni; Jose F Camargo; Weijing He; Alison Smith; Juan-Manuel Anaya; Toshiyuki Miura; Frederick M Hecht; Manju Mamtani; Florencia Pereyra; Vincent Marconi; Andrea Mangano; Luisa Sen; Rosa Bologna; Robert A Clark; Stephanie A Anderson; Judith Delmar; Robert J O'Connell; Andrew Lloyd; Jeffrey Martin; Seema S Ahuja; Brian K Agan; Bruce D Walker; Steven G Deeks; Sunil K Ahuja
Journal:  Nat Immunol       Date:  2007-10-21       Impact factor: 25.606

4.  Low CD4+ T-lymphocyte values in human immunodeficiency virus-negative adults in Botswana.

Authors:  Hermann Bussmann; C William Wester; Kereng V Masupu; Trevor Peter; Sarah M Gaolekwe; Soyeon Kim; Ann Marie Reich; Sam Ahn; Ying Wu; Ibou Thior; Max Essex; Richard Marlink
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

5.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

Authors:  Florencia Pereyra; Marylyn M Addo; Daniel E Kaufmann; Yang Liu; Toshiyuki Miura; Almas Rathod; Brett Baker; Alicja Trocha; Rachel Rosenberg; Elizabeth Mackey; Peggy Ueda; Zhigang Lu; Daniel Cohen; Terri Wrin; Christos J Petropoulos; Eric S Rosenberg; Bruce D Walker
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

Review 6.  Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.

Authors:  Steven G Deeks; Bruce D Walker
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

7.  Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda.

Authors:  Tom Lutalo; Ronald H Gray; Maria Wawer; Nelson Sewankambo; David Serwadda; Oliver Laeyendecker; Noah Kiwanuka; Fred Nalugoda; Godfrey Kigozi; Anthony Ndyanabo; John Baptist Bwanika; Steven J Reynolds; Tom Quinn; Pius Opendi
Journal:  AIDS       Date:  2007-11       Impact factor: 4.177

8.  Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype.

Authors:  Ashwin Vasan; Boris Renjifo; Ellen Hertzmark; Beth Chaplin; Gernard Msamanga; Max Essex; Wafaie Fawzi; David Hunter
Journal:  Clin Infect Dis       Date:  2006-02-09       Impact factor: 9.079

9.  Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.

Authors:  Noah Kiwanuka; Oliver Laeyendecker; Merlin Robb; Godfrey Kigozi; Miguel Arroyo; Francine McCutchan; Leigh Anne Eller; Michael Eller; Fred Makumbi; Deborah Birx; Fred Wabwire-Mangen; David Serwadda; Nelson K Sewankambo; Thomas C Quinn; Maria Wawer; Ronald Gray
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

10.  Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection.

Authors:  Marylyn M Addo; Rika Draenert; Almas Rathod; Cori L Verrill; Benjamin T Davis; Rajesh T Gandhi; Gregory K Robbins; Nesli O Basgoz; David R Stone; Daniel E Cohen; Mary N Johnston; Theresa Flynn; Alysse G Wurcel; Eric S Rosenberg; Marcus Altfeld; Bruce D Walker
Journal:  PLoS One       Date:  2007-03-28       Impact factor: 3.240

View more
  11 in total

1.  Coreceptor usage, diversity, and divergence in drug-naive and drug-exposed individuals from Malawi, infected with HIV-1 subtype C for more than 20 years.

Authors:  Ishla Seager; Simon A Travers; Michael D Leeson; Amelia C Crampin; Neil French; Judith R Glynn; Grace P McCormack
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

2.  HIV type 1 mutational patterns in HIV type 1 subtype C-infected long-term survivors in Karonga District Malawi: further analysis and correction.

Authors:  Ishla Seager; Michael D Leeson; Amelia C Crampin; Dominic Mulawa; Neil French; Judith R Glynn; Simon A A Travers; Grace P McCormack
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-30       Impact factor: 2.205

3.  Efficiency of CCR5 coreceptor utilization by the HIV quasispecies increases over time, but is not associated with disease progression.

Authors:  Andrew D Redd; Oliver Laeyendecker; Xiangrong Kong; Noah Kiwanuka; Tom Lutalo; Wei Huang; Ronald H Gray; Maria J Wawer; David Serwadda; Susan H Eshleman; Thomas C Quinn
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

4.  Natural control of HIV infection in young women in South Africa: HPTN 068.

Authors:  Mariya V Sivay; Jessica M Fogel; Jing Wang; Yinfeng Zhang; Estelle Piwowar-Manning; William Clarke; Autumn Breaud; Joel Blankson; Erica L Hamilton; Kathleen Kahn; Amanda Selin; F Xavier Gomez-Olive; Catherine MacPhail; James P Hughes; Audrey Pettifor; Susan H Eshleman
Journal:  HIV Clin Trials       Date:  2018-12-06

5.  The rates of HIV superinfection and primary HIV incidence in a general population in Rakai, Uganda.

Authors:  Andrew D Redd; Caroline E Mullis; David Serwadda; Xiangrong Kong; Craig Martens; Stacy M Ricklefs; Aaron A R Tobian; Changchang Xiao; Mary K Grabowski; Fred Nalugoda; Godfrey Kigozi; Oliver Laeyendecker; Joseph Kagaayi; Nelson Sewankambo; Ronald H Gray; Stephen F Porcella; Maria J Wawer; Thomas C Quinn
Journal:  J Infect Dis       Date:  2012-06-05       Impact factor: 5.226

6.  Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Authors:  Mauro Pistello; Francesca Bonci; Elisa Zabogli; Francesca Conti; Giulia Freer; Fabrizio Maggi; Mario Stevenson; Mauro Bendinelli
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

7.  Older age at infection and nulliparity are associated with long-term non-progression in female sex workers infected with non-subtype B HIV-1.

Authors:  Vernon Mochache; Barbra A Richardson; Linnet N Masese; Susan M Graham; Kishorchandra Mandaliya; John Kinuthia; Walter Jaoko; Julie Overbaugh; R Scott McClelland
Journal:  Int J STD AIDS       Date:  2020-04-15       Impact factor: 1.359

8.  Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention.

Authors:  Katharina Kranzer; Stephen D Lawn; Leigh F Johnson; Linda-Gail Bekker; Robin Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

9.  Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda.

Authors:  Alex Kayongo; Elena Gonzalo-Gil; Emrah Gümüşgöz; Anxious J Niwaha; Fred Semitala; Robert Kalyesubula; Bernard S Bagaya; Moses L Joloba; Richard E Sutton
Journal:  J Acquir Immune Defic Syndr       Date:  2018-11-01       Impact factor: 3.731

10.  Reduction in HIV community viral loads following the implementation of a "Treatment as Prevention" strategy over 2 years at a population-level among men who have sex with men in Hangzhou, China.

Authors:  Lin He; Jiezhe Yang; Qiaoqin Ma; Jiafeng Zhang; Yun Xu; Yan Xia; Wanjun Chen; Hui Wang; Jinlei Zheng; Jun Jiang; Yan Luo; Ke Xu; Xingliang Zhang; Shichang Xia; Xiaohong Pan
Journal:  BMC Infect Dis       Date:  2018-02-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.